Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of Lupuzor (CEP-33457) in systemic lupus erythematosus
2010-019293-32Phase 3Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of foralumab in systemic lupus erythematosus (SLE), sponsored by Cephalon, Inc. Primary endpoint: Primary safety and tolerability endpoints. Started Jul 2010; status: terminated.
02
Drugs
foralumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2010-019293-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019293-32.